Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6765 in Treatment-Resistant Major Depressive Disorder
NCT00491686Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing AZD6765 with Placebo (2 arms). Primary endpoint: Change from Baseline in Montgomery-Åsberg Depression Rating Scale Total Score. Started Jul 2007; status: completed.
02
Drugs
lanicemine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00491686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491686.